Biopharmas raising money in public or private financings, including: Alterity, Grace, Mustang.

Raising money to advance promising science is a constant struggle, bringing biopharma executive leadership together to learn about investment strategies in the opening session at the Biotechnology Innovation Organization’s CEO and Investor Conference in New York. “We’re bottoms-up investors. If we like the technology, we like the product, we think it’s going to work, we want to find a way to invest,” said Chris Garabedian, chairman and CEO of Xontogeny.

Biopharmas raising money in public or private financings, including: Aardvark, Ascentage, Jyong, Neuronetics, Palatin.

Sionna Therapeutics Inc. has opened on Nasdaq in the year’s fourth IPO, this one priced at the upper end of its original per-share range at $18. The cystic fibrosis therapy developer is looking for gross proceeds of about $191 million by offering 10.58 million shares of common stock. On Feb. 7, shares (NASDAQ:SION) closed the day 39% upward at $25.

Biopharmas raising money in public or private financings, including: Belite Bio, Briacell, Coeptis, Miist, Mustang.

Biopharmas raising money in public or private financings, including: 60 Degrees, Algernon, Azitra, Cytoimmune, GH Research, Iveena, Nuvectis.

Biopharmas raising money in public or private financings, including: Auron, Briacell, Medigene, Serina, Sionna.

Biopharmas raising money in public or private financings, including: Annovis. Aplagon, Immunome, Tectonic, Vetigenics.